ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Supreme Court Weighs Overtime Pay For Drug Reps

By Brent Kendall Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Supreme Court appeared conflicted Monday over whether drug companies have to pay their sales representatives for working overtime hours, a high-stakes question for the industry. The Fair Labor Standards Act, in general, requires companies to pay workers overtime, but it includes many exemptions for white-collar workers, including those employed as outside salespeople. The high court, during an hour-long oral argument Monday, grappled with whether drug companies can place their sales representatives in the exempt category. Lawyer Thomas Goldstein, representing former salespeople for GlaxoSmithKline PLC (GSK, GSK.LN) who are seeking overtime pay, said drug representatives can't be placed under the outside-sales exemption because they don't actually sell medicines. Doctors, he said, don't make any binding commitments to the drug representatives who visit them. Chief Justice John Roberts echoed the point, saying physicians merely tell the drug representatives that they'll think of their products when the relevant medical situation arises. The Obama administration is supporting the employees' arguments in favor of overtime pay. Paul Clement, the lawyer representing Glaxo, said drug representatives are hired as salespeople and are given sales training. Their main purpose, he said, is to convince doctors to prescribe the drugs they are promoting. To require overtime pay for those workers could impose billions of dollars of potential liability on the industry, he said. Justice Antonin Scalia was perhaps the court's strongest voice against overtime pay. He said pharmaceutical sales may function differently than sales in other industries, but "these people look like salesmen to me." Justice Ruth Bader Ginsburg noted that the sales rep don't punch a time clock and can spend part of their time promoting drugs over golf or dinner. "Would the time on the golf course get time-and-a-half?" she asked. Other justices suggested the Department of Labor's support for overtime pay, announced in a series of court briefs, upset a long-held understanding that drug representatives were not entitled to overtime wages. Justice Stephen Breyer said the department should have engaged in administrative rulemaking, with notice and comment from the public, before embarking on such a course. Lower courts are divided on the overtime issue. In the current case, the San Francisco-based Ninth U.S. Circuit Court of Appeals ruled the Glaxo representatives weren't entitled to the extra pay. But in a 2010 case, the New York-based Second Circuit revived employee overtime claims against U.S. units of Merck & Co. (MRK) and Novartis AG (NVS, NOVN.VX). That court noted that drug sales reps can't take orders or obtain binding commitments from doctors. The case is Christopher v. SmithKline Beecham, 11-204. A decision is expected by the end of June. -By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
02/09/201613:00:00Novartis Reaches Entresto Pay-for-Performance Deals With Cigna...
02/09/201612:57:00Novartis Reaches Entresto Pay-for-Performance Deals With Cigna...
02/03/201611:04:00Investors' Fears Eased as Glaxo Posts Solid Results -- Update
02/03/201608:30:00GlaxoSmithKline Posts $510 Million Net Loss
02/03/201608:23:00GlaxoSmithKline Posts GBP354 Million Net Loss in 4Q
01/28/201616:40:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/27/201616:30:00Radius Health Announces Clinical Collaboration With a Leading...
01/27/201609:57:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201605:10:00Global Stocks Edge Lower Ahead of U.S. Interest Rate Decision
01/27/201604:44:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201603:01:00Novartis Net Profit Falls 57% --Update
01/27/201602:50:00Novartis Net Profit Falls 57%
01/27/201602:02:00Novartis 4Q Net Profit Falls 57% as Eye-Care Unit Drags on Results
01/22/201611:53:00CEOs Sanguine on M&A Prospects in Spite of Markets Dive --Update
01/22/201609:06:00Novartis AG 4Q 2015 -- Forecast
01/20/201619:29:00Drug and Diagnostic Companies Issue Joint Declaration on Antibiotics
01/11/201610:10:00Juno Agrees to Acquire AbVitro
12/17/201519:49:00Ligand Pharma to Buy Genetic Engineering Company OMT -- 2nd Update
12/17/201505:10:00Global Stocks Rally After Fed Decision
12/07/201515:53:00U.S. Stocks Fall as Oil Keeps Sliding

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad